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BACKGROUND: Substantial evidence supports an association between use of menopausal hormone therapy and decreased
colorectal cancer (CRC) risk, indicating a role of exogenous sex hormones in CRC development. However, findings on endogenous
oestrogen exposure and CRC are inconsistent.
METHODS: We used a Mendelian randomisation approach to test for a causal effect of age at menarche and age at menopause as
surrogates for endogenous oestrogen exposure on CRC risk. Weighted genetic risk scores based on 358 single-nucleotide
polymorphisms associated with age at menarche and 51 single-nucleotide polymorphisms associated with age at menopause were used
to estimate the association with CRC risk using logistic regression in 12,944 women diagnosed with CRC and 10,741 women without CRC
from three consortia. Sensitivity analyses were conducted to address pleiotropy and possible confounding by body mass index.
RESULTS: Genetic risk scores for age at menarche (odds ratio per year 0.98, 95% confidence interval: 0.95–1.02) and age at
menopause (odds ratio 0.98, 95% confidence interval: 0.94–1.01) were not significantly associated with CRC risk. The sensitivity
analyses yielded similar results.
CONCLUSIONS: Our study does not support a causal relationship between genetic risk scores for age at menarche and age at
menopause and CRC risk.
British Journal of Cancer (2018) 118:1639–1647; https://doi.org/10.1038/s41416-018-0108-8
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer
worldwide and incidence rates are higher in men than in women.1
The sex-specific difference might be partly attributed to differ-
ential exposure to sex hormones, especially oestrogen.2 This
hypothesis is partially supported by epidemiologic studies as well
as a recent meta-analysis out of four randomised controlled trials,
eight cohort and eight case–control studies, which have shown
that use of exogenous sex hormones in the form of combined
oestrogen–progestogen menopausal hormone therapy (MHT) is
inversely associated with the risk of CRC.3, 4
Epidemiologic studies examining reproductive factors such as
age at menarche and age at menopause with CRC risk have
reported inconsistent results.5–7 A meta-analysis summarising
evidence based on 22 studies published by Li et al.8 did not find a
significant association between age at menarche and CRC risk. In a
large prospective cohort of the NIH American Association of
Retired Persons (AARP) Diet and Health Study with more than
214,000 postmenopausal women, an inverse association between
age at menarche and CRC risk was observed for women without a
history of MHT use, whereas increasing age at menopause was
associated with higher CRC risk.9 It is possible that the
inconsistency in results is due to recall bias or to improper
adjustment for confounders, which are inherent limitations of
observational studies. The Mendelian randomisation (MR)
approach10 uses genetic variants as instrumental variables to test
for the causal effect of an exposure risk factor on an outcome.
Since the genetic variants in offspring are randomly distributed at
conception independent of environmental factors given parental
genotypes, confounding and reverse causation are less likely to
occur in MR analyses. For genetic variants to function as valid
instrumental variables in MR analyses, three assumptions have to
be met: (1) the genetic variants have to be associated with the
exposure risk factor; (2) the variants are not associated with any
confounding variables of the exposure–outcome association; and
(3) the variants are unrelated to the outcome except through the
risk factor of interest.11, 12 Using variants associated with age at
menarche and age at menopause instead of self-reported
measure of the risk factors themselves, this approach can help
to avoid issues of confounding, recall bias, and reverse causation.
Evidence from MHT use suggests that more exposure to
oestrogen reduces risk of CRC.3, 4, 13 Estrogen exerts its effects
in colon cells predominantly through the nuclear receptor
oestrogen-receptor β (ERβ),14, 15 which has mainly anti-
proliferative effects16 and its expression is inversely related to
cancer stage, tumour extent, and mortality.17, 18 Longer use of
MHT appears to be associated with high ERβ expression in
tumours.19 If similar mechanisms hold then longer endogenous
oestrogen exposure (through earlier age at menarche and/or later
age at menopause) would reduce CRC risk as well. To test this
hypothesis, we conducted an MR analysis using summary data for
single-nucleotide polymorphisms (SNPs) known to be associated
with age at menarche and age at menopause from prior studies as
well as using individual level data of three consortia.
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MATERIALS AND METHODS
Study population
Epidemiological and genetic data were derived from 26 studies
participating in three large consortia of CRC, the Genetics and
Epidemiology of Colorectal Cancer Consortium (GECCO)20 (5386
cases and 5696 controls), the Colon Cancer Family Registry
(CCFR)21 (1678 cases and 1188 controls) and the Colorectal Cancer
Transdisciplinary (CORECT) Consortium22 (5880 cases and 3857
controls) (see Supplementary Tables 1 and 2). Different centres of
CCFR participated as individual studies in GECCO and/or CORECT,
and therefore were analysed as such. Any participant overlap
between the three consortia was excluded. In total, 12,944 female
colorectal cancer cases and 10,741 female controls, both of
European ancestry were included. All participants provided
written, informed consent and studies were approved by their
respective institutional review boards. Women with incident
invasive colorectal adenocarcinoma (International Classification
of Disease Code, 9th revision (ICD-9), codes 153–154) were
included as cases. Data on demographic factors and lifestyle were
collected using in-person interviews or self-completed question-
naires. Data harmonisation was done centrally as previously
described.23 Self-reported data for age at menarche and age at
menopause have not been harmonised and therefore could not
be used.
Genotype data and imputation
Genotype information was available for all included studies.
Details on genotyping, quality assurance, and imputation are
included in the Supplementary Information. In short, SNPs were
excluded based on call rate (<98% GECCO; <95% in CORECT),
Hardy–Weinberg equilibrium in controls (P < 1 × 10−4), or low
minor allele frequency (≤1%). Participants received a value of 0,
1, or 2 for carrying 0 (wild-type homozygous), 1 (heterozygous),
or 2 (homozygous for the risk allele) alleles associated with
higher age at menarche/age at menopause for each SNP. For
imputed SNPs, participants were assigned continuous values
between 0 and 2.
Calculation of genetic risk scores
Two recent genome-wide association studies conducted by the
REPROGEN consortium (Reproductive Genetics Consortium)
involving up to ~370,000 women for the study on age at
menarche and up to 69,360 women for the study on age at
menopause identified 389 genetic variants associated with age at
menarche24 and 54 SNPs associated with age at natural
menopause25 at a genome-wide significance level (i.e., P < 5 ×
10−8). Of the reported 389 genetic variants for age at menarche,
12 variants on sex chromosomes (which were not available in our
datasets) were excluded. For further 42 missing variants, we used
proxy SNPs in strong linkage disequilibrium (R² > 0.8, median R²=
0.985, R² range: 0.83–1.00) with effect alleles harmonised to reflect
increase in age at menarche. Seven variants were excluded
because no proxy was found. We checked for correlations
between individual SNPs and excluded 12 correlated SNPs (R² >
0.01) (always the SNP with higher P-value for association with age
at menarche was dropped). So data were available for 358 SNPs
for this analysis (mean imputation quality score= 0.97) (Supple-
mentary Table 5). For age at menopause, three correlated SNPs
(R² > 0.01) were excluded. All remaining 51 SNPs for age at
menopause were available in the datasets (mean imputation
quality score= 0.98) (Supplementary Table 6). The genotype data
described were used to construct genetic risk scores (GRS) as
instrumental variables for age at menarche and age at
menopause, respectively.
The GRS for the kth women is calculated by the sum of the
number of risk increasing alleles carried (G) (imputed allele doses)
for each SNP weighted by the reported beta-coefficient (β) for











As risk scores themselves do not have meaningful units, we
scaled the risk scores in terms of age in years. In this way resulting
odds ratios (OR) can be interpreted as the relative change in CRC
risk per year older age at menarche/age at menopause. Scaling
was done by dividing the GRS by regression coefficients of a linear
regression of GRS on self-reported age at menarche (beta= 0.57)
or age at menopause (beta= 0.98). These regression coefficients
were obtained using the DACHS (Darmkrebs: Chancen der
Verhütung durch Screening) study (853 control women) and the
WHI (Womens’ Health Initiative) study (1492 control women) for
which self-reported data on age at menarche were available and
regression coefficients of the two studies were combined using
meta-analysis.
An additional GRS as a surrogate for total lifetime exposure to
endogenous oestrogen was calculated as the sum of the scaled
risk scores for age at menarche and age at menopause.
GRStime period ¼ GRSage atmenarche þ GRSage atmenopause:
For this analysis, risk scores for age at menarche were calculated
as the sum of the number of alleles associated with decreasing
age at menarche and the number of alleles associated with
increasing age at menopause. So the GRS for time period of
oestrogen exposure reflects higher risk for longer exposure to
endogenous oestrogen. For this score, four SNPs (rs3136269,
rs11031040, rs537244, rs4303811) were excluded due to high
linkage disequilibrium (R² > 0.01) between age at menarche and
age at menopause SNPs.
Statistical analysis
Validating MR assumptions. The first assumption of MR regarding
instrumental variable strength (i.e. association between the
genetic variants and the exposure risk factor) was verified by
calculating the F-statistic out of F= (R²(n−K−1))/((1−R²)K)), where
R² refers to the variance explained by the instrumental variable,24,
25 K indicates the number of instrumental variables, and n stands
for the sample size.26 An F-statistic >10 suggests that the genetic
instrument is sufficiently strong.27 To evaluate the second
assumption of MR (i.e. no association between genetic variants
and potential confounders), we tested associations between GRS
for age at menarche/age at menopause and the following risk
factors for CRC: smoking status (ever/never), family history of CRC,
education/educational level, ever aspirin/NSAID use (at least once
per month for more than one year), body mass index (BMI)
(continuous), MHT (oestrogen/progestin combined and oestrogen
alone), using linear regression for continuous variables and
logistic/multinomial logistic regression for categorical variables
in a subset of the studies with available data (n= 6285 controls).
To address the third assumption of MR, i.e. to assess the presence
of pleiotropy, we applied the MR-Egger method.28 MR-Egger relies
on the InSIDE assumption (Instrument Strength Independent of
Direct Effect), which is the assumption that the pleiotropic effects
of the genetic variants are not correlated with the effects of
genetic variants on the risk factors. MR-Egger uses an inverse-
variance weighted estimator and by plotting the SNP’s effect on
the exposure against its effect on the outcome, the intercept term
of MR-Egger provides a test for directional pleiotropy, i.e. the
average effect of pleiotropy is non-zero, across all genetic variants
used. If the average pleiotropic effect of all variants is zero and the
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InSide assumption is satisfied, pleiotropy is “balanced” and will not
be detected. If the intercept differs from zero, it suggests
horizontal pleiotropy, which means that some genetic variants
affect the outcome through a pathway different from the
exposure of interest. For visual inspection of pleiotropy, we used
funnel plots of each SNPs ratio estimate against its precision (1/
standard error of the ratio estimate).29, 30 Any deviation from
symmetry would suggest pleiotropy.
Estimation of causal effect
GRS based analyses. We examined the association between GRS
and CRC risk using logistic regression models adjusted for study,
age as well as principal components (PCs) of genetic ancestry
(three PCs were used for GECCO and 10 PCs were used for
CORECT) to account for potential population stratification.
Summary results for GECCO and CORECT were derived using
fixed-effects meta-analysis assuming that the included studies
share a common effect size. As there are indications for differential
associations of age at menarche with CRC risk according to
menopausal hormone use,9, 31 stratified analyses by MHT were
performed (only in GECCO where harmonised data were
available). Additional stratified analyses were performed according
to menopausal status (for age at menarche), combined meno-
pausal oestrogen or progesterone therapy, oestrogen therapy
alone, and BMI categories in kg/m² (BMI < 18.5: underweight,
18.5–24.9: normal weight, 25–30: overweight, >30: obese) (only for
age at menopause). Due to reported differences in risk between
colon and rectal cancer associated with hormone use,32, 33 we also
conducted site-specific analyses for 4037 female colon cancer
cases and 1184 rectal cancer cases in GECCO. Power calculations
were conducted to estimate the magnitude of effects detectable
with our study size assuming 5% alpha level and an R² of 0.069 for
age at menarche and R² of 0.057 for age at menopause, which
corresponds to the variance in age at menarche/age at
menopause explained by the SNPs used for this analyses.34
It is known that BMI in childhood is strongly associated with age
at menarche35 and that some SNPs associated with age at
menarche could also have pleiotropic effects and therefore are
related to BMI as well.24 To address this issue and thereby also
account for violations of the third MR assumption, we conducted
further BMI-specific sensitivity analyses. We adjusted for BMI in the
logistic regression analysis using a weighted GRS for BMI
comprising 77 SNPs previously reported to be associated with
BMI at a genome-wide significance level in European subjects.36
For the second sensitivity analysis, we identified age at menarche
SNPs showing pleiotropy by testing the association of these SNPs
with BMI in a subset of our sample (n= 5832 cases/6285 controls)
and found 29 SNPs to be associated with BMI at nominal
significance (P-value <0.05). Two further SNPs overlapped with
reported BMI-SNPs36 and 11 more SNPs were in high linkage
disequilibrium (R² > 0.1) with BMI SNPs. A restricted GRS for age at
menarche excluding the 42 BMI-associated SNPs (n= 316 SNPs)
was constructed and then assessed for association with CRC risk.
For the analysis of lifetime oestrogen exposure we also generated
a restricted risk score excluding the same 42 BMI-associated SNPs.
Two-sample MR analyses. We performed two-sample MR analyses
as sensitivity analyses using published summary statistics for
SNP–exposure associations (age at menarche24/age at meno-
pause25); SNP outcome associations were estimated in GECCO/
CORECT (Supplementary Tables 8 and 9 for age at menarche/
menopause-SNPs, respectively). We applied the weighted median
estimator approach, which is robust against violations due to
pleiotropic SNPs even when up to 50% of the genetic instruments
are invalid.37 For this approach, we used SNP-exposure and SNP-
outcome associations to build ratio estimates for each SNP. These
estimates were ordered and weighted by the inverse of their
variance. Bootstrapped standard errors were calculated and used
for construction of 95% confidence intervals (CI). Furthermore, we
assessed the slope of MR-Egger regression (see section on
validation of MR assumptions) which yields a pleiotropy-
adjusted estimate of the true causal effect.28
All analyses were conducted using R version 3.2.2 (R Foundation
for Statistical Computing, Vienna, Austria). For supplementary
figures, we used the R packages “Mendelian Randomisation”38 and
“ggplot2”.
RESULTS
The assessment of the MR assumptions indicated that our
instrumental variables for age at menarche and for age at
menopause were both strong instruments (F-statistic for age at
menarche= 1755, R²= 0.06924; F-statistic for age at menopause=
1431, R²= 0.05725. Secondly, we did not find significant associa-
tions between the GRS for age at menarche and CRC risk factors,
including smoking, family history of cancer, education, aspirin/
NSAID use, oestrogen/progestin therapy, oestrogen alone therapy,
with the exception of BMI, which showed a significant association
(Supplementary Table 3). Similarly, there was no association of the
GRS for age at menopause with any of the tested risk factors
(Supplementary Table 3). Table 1 shows the results of the MR
analyses for age at menarche, age at menopause, and lifetime
oestrogen exposure with CRC risk. Yearly increment in GRS for age
at menarche was associated with CRC risk with an OR of 0.98 (95%
CI: 0.95–1.02). Sensitivity analyses adjusting for BMI using a GRS
yielded similar results for age at menarche (OR 0.99 per year, 95%
CI: 0.95–1.02). Further sensitivity analysis using restricted risk
scores for age at menarche (by excluding 42 BMI-associated SNPs)
showed similar effect sizes for the association between age at
menarche and CRC risk (OR 0.99 per year, 95% CI: 0.95–1.03). We
also did not find evidence to support a causal association with risk
of CRC for age at menopause (OR 0.98 per year, 95% CI: 0.94–1.01)
or for lifetime oestrogen exposure (OR 0.99 per year, 95% CI:
0.97–1.02) using GRS-based analyses.
Results of the weighted median estimator approach also did not
indicate causal association between age at menarche (OR per year
1.00, 95% CI: 0.90–1.11), age at menopause (OR per year 1.00, 95%
CI: 0.95–1.05), or lifetime oestrogen exposure (OR per year 1.00,
95% CI: 0.95–1.05) with CRC risk.
The pleiotropy adjusted MR estimate (OR) derived from the
slope of Egger regression was 0.99 (95% CI: 0.83–1.17) for age at
menarche, 1.02 (95% CI: 0.94–1.10) for age at menopause, and
0.97 (95% CI: 0.93–1.01) for lifetime oestrogen exposure (details of
results per GECCO and CORECT consortium in Supplementary
Table 7). The intercept term from MR-Egger regression was
centred at the origin for age at menarche (intercept term −0.0008,
95% CI: −0.007 to 0.005, P-value 0.80) and age at menopause
(intercept term −0.009, 95% CI: −0.023 to 0.006, P-value 0.23),
suggesting absence of strong directional pleiotropy (Supplemen-
tary Figures 1 and 2). Also the funnel plots for age at menarche
and age at menopause appear to be generally symmetrical and
therefore do not suggest presence of pleiotropy (Supplementary
Figures 3 and 4). Table 2 shows stratified analyses for the
association of GRS for age at menarche and CRC risk by
menopausal status, combined oestrogen/progesterone therapy,
and oestrogen alone therapy as well as cancer site based on
GECCO data. None of these factors modified substantially the
association between age at menarche and CRC risk. The site
specific analysis showed no evidence for a difference in
association between colon cancer (OR 0.97 per year, 95% CI:
0.91–1.02) and rectal cancer (OR 1.04 per year, 95% CI: 0.95–1.14).
The analyses for age at menopause stratified by combined
oestrogen/progesterone therapy, oestrogen alone therapy, BMI,
and cancer site did not yield evidence for effect heterogeneity
(Table 3). Power calculation shows that our study had >80 %
power to detect an OR of 0.85 per standard deviation change in
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exposure variable (1.5 years for age at menarche, 4.8 years for age
at menopause) but only around 50% power for an OR of 0.90
(Supplementary Table 4).
DISCUSSION
In this large MR study we aimed to clarify the inconsistent findings
from observational studies regarding the association of age at
menarche and age at menopause with CRC risk and thereby the
role of endogenous oestrogen exposure. We investigated the
association of GRS for age at menarche and age at menopause as
surrogates for endogenous oestrogen exposure on CRC risk. Our
results do not support an association between GRS for age at
menarche and age at menopause and CRC risk, which under MR
assumptions can be interpreted as absence of a causal effect.
In line with the findings of our study, several prospective studies
and one meta-analysis reported no association6, 8, 39 between self-
reported age at menarche and CRC risk, although some studies
found an inverse association.5, 9 Two more recent prospective
studies reported inverse associations with CRC risk for age at
Table 1. Association between age at menarche/age at menopause and CRC risk using MR analyses and sensitivity analyses
GRS-based analysesb 2-sample MRf







Variable (per year) Cases/Controls OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Age at menarche 12,944/10,741 0.98 0.95–1.02 0.99 0.95–1.02 0.99 0.95–1.03 0.99 0.83–1.17 1.00 0.90–1.11
Age at menopause 12,944/10,741 0.98 0.94–1.01 NA NA NA NA 1.02 0.94–1.10 1.00 0.95–1.05
Time period of hormone exposure 12,944/10,741 0.99 0.97–1.02 0.99 0.97–1.02 0.99 0.97–1.01 0.97 0.93–1.01 1.00 0.95–1.05
BMI body mass index, CCFR Colon Cancer Family Registry, CI confidence interval, CORECT Colorectal Transdisciplinary study, GECCO Genetics and Epidemiology
of Colorectal Cancer Consortium, GRS genetic risk score, MR Mendelian randomisation, NA not applicable, OR odds ratio per year, SNPs single-nucleotide
polymorphisms, se standard error. aLogistic regression model adjusted for age, study, and principal components of genetic ancestry. bMeta-analysed estimate
of GECCO/CORECT datasets (CCFR centres participated in GECCO or CORECT and were analysed as such). cAdditionally adjusted for a GRS for BMI out of 77
reported SNPs for BMI36. d42 BMI-associated SNPs were excluded from the age at menarche and time period of oestrogen exposure—risk scores. eEstimate
derived from the slope of MR-Egger. fEstimates derived using summary statistics; se for calculation of CI obtained via bootstrapping
Table 2. Association of genetically predicted age at menarche with
CRC risk according to subgroups, CCFR, GECCO Consortium
Subgroup N (cases/
controls)










Menopausal hormone therapy combined
No 3266/
3490
0.96 0.90–1.03 0.24 0.69















CCFR Colon Cancer Family Registry, CI confidence interval, GRS genetic risk
score, OR odds ratio per year. aAll analyses adjusted for age, sex, study, and
principal components of genetic ancestry. bP-value calculated using
likelihood ratio tests comparing the model with and without interaction
term. cP-value for heterogeneity was obtained in case-only analysis of
colon vs. rectal cancer
Table 3. Association of genetically predicted age at menopause and
CRC risk according to subgroups, CCFR, GECCO Consortium
N (cases/
controls)








0.99 0.93–1.05 0.78 0.75




0.99 0.93–1.05 0.27 0.76



















BMI body mass index, CCFR Colon Cancer Family Registry, CI confidence
interval, GRS genetic risk score, OR odds ratio per year. aAll analyses
adjusted for age, sex, study, and principal components of genetic ancestry.
bP-value calculated using likelihood ratio tests comparing the model with
and without interaction term. cP-value for heterogeneity was obtained in
case-only analysis of colon vs. rectal cancer
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menarche only among never users of any MHT. In never users of
hormone therapy, Zervoudakis et al.9 reported a hazard ratio of
0.73 (95% CI: 0.57–0.94) for age at menarche (>15 vs. 11–12 years)
in association with risk of CRC and Murphy et al.31 found a hazard
ratio of 0.72 (95% CI: 0.54–0.96) for age at menarche (>15 vs.
11–12 years). We therefore assessed the association of GRS for age
at menarche with CRC risk stratified by ever/never use of MHT,
separately for combined oestrogen–progesterone therapy and for
oestrogen monotherapy. No difference in the association accord-
ing to either combined oestrogen–progesterone therapy or
oestrogen-alone therapy was found.
Higher BMI in childhood is associated with earlier age at
menarche24, 35 and also with a higher risk for CRC.40 Therefore
we conducted BMI-specific sensitivity analyses to account for
violations of the MR assumptions by confounding and pleiotropy.
Due to a strong association between childhood/adolescent BMI
and adult BMI41 and also a high concordance between
adolescent and adult BMI-SNPs,42 we accounted for adult BMI
in sensitivity analyses. The effect sizes observed in the sensitivity
analysis (by excluding BMI-associated SNPs and by adjustment
using a GRS for BMI) were slightly smaller compared to results of
the main analysis, which suggests that some of the effect was
confounded by BMI. Our restricted risk-score might not be totally
BMI-unrelated, considering that Day et al.24 found age at
menarche variants that appear unrelated to BMI at a nominal
level in their sample to be still BMI associated collectively (P=
4.2 × 10−9). Because of this strong interrelationship between age
at menarche and BMI it is difficult to separate the SNPs into BMI-
related and BMI-unrelated variants. So our adjustment of the
analysis by GRS-BMI might more effectively control for BMI. Thus,
any observed inverse relationship between age at menarche and
CRC risk in previous observational studies could have been due
to inadequate control of confounding by higher BMI in
childhood.
For age at menopause, results of observational studies on the
association with CRC risk have also been inconclusive. The large
NIH-AARP study observed a statistically significant elevated risk for
higher age at menopause in postmenopausal women (≥55 vs.
<40; HR 1.50; 95% CI: 1.23–1.83),9 whereas most other studies
reported null associations.6, 31, 39 Corresponding to the lack of
association with age at menarche and age at menopause, the GRS
for the reproductive period as indicator for the lifetime oestrogen
exposure was also not significantly associated to CRC risk.
Additional adjustment of that analysis by education, family history
of CRC, ever regular aspirin use, MHT usage, BMI, and smoking did
not substantially change the results (Supplementary Table 10).
This is compatible with the observation of no association between
the reproductive period (≥36 years vs. ≤30 years) and CRC risk in a
prospective observational study conducted in Japan43. The GRS
for lifetime for endogenous oestrogen exposure, which we
constructed, does not account for other factors like parity or
breast feeding, which influence overall oestrogen exposure;
however, these factors have not been associated with CRC risk.
Results of prospective studies that investigated the association
between serum levels of endogenous oestrogens and CRC risk
have also been inconsistent. One study reported a positive
association between circulating estradiol and CRC risk,44 another
study observed an inverse relationship45 while most other studies
found no associations.46–48 There are reports that earlier age at
menarche is associated with higher oestrogen levels.49, 50 So
oestrogen levels could also be a possible link between age at
menarche and CRC risk. Due to the inconsistent results of these
reports, further studies are needed to clarify these associations.
On the other hand, observational studies reported that
exogenous oestrogen exposure by MHT mainly in the form of
combined oestrogen–progestogen was associated with a reduced
risk for CRC.13, 51 The Womens’s Health Initiative Clinical Trial (WHI-
CT) reported no effect of oestrogen-alone therapy,52, 53 and a
significant risk reduction for the association of oestrogen plus
progestin vs. placebo and CRC risk,33 which was suggested to
have resulted from diagnostic delay instead of true risk reduc-
tion54. However, a recent meta-analysis which summarised results
of four clinical trials including WHI-CT and 16 observational studies
concluded that there is consistent evidence to support a
protective effect of MHT on CRC risk.4
Thus, it appears that exogenous and endogenous oestrogens,
which also vary in absolute amount of oestrogen, may play
different roles in the development of CRC, presumably by different
mechanisms, which are not well understood. Oestrogen acts in
colon cells predominantly through ERβ,14, 15 which exerts
proapoptotic and anti-proliferative effects in the colon16 and its
expression is reduced in tumour tissue.17, 18 According to an
in vivo study, oestrogen treatment was associated with an
increase in expression of ERβ in colon tissue,55 supporting a
mechanism by which MHT may affect CRC risk. There is also some
evidence that the protective effect of MHT on CRC risk may vary
by the expression status of ERβ. Two studies found that the
magnitude of risk reduction by MHT was different between
colorectal tumours with higher and with lower expression of
ERβ.56, 57 It is possible that the effect of endogenous oestrogens
on CRC risk may be modulated by ERβ expression as well.
Therefore, larger studies with data on expression of ERβ in colon
tissue are warranted to assess whether the association of age at
menarche/age at menopause and CRC risk differs by ERβ
expression status.
In this MR study, we aimed to use proxies for start and endpoint
of endogenous oestrogen exposure in women, specifically age at
menarche/age at menopause, which themselves are complex
traits influenced by many variants with only small effects on the
trait. Although we did not see large pleiotropic effects using Egger
regression, there might have been residual pleiotropy, which is
difficult to exclude. Previous studies of age at menarche
performed LD score regression using 123 SNPs associated with
age at menarche and found, amongst others, genetic correlations
with BMI, adult height, or type 2 diabetes. Residual pleiotropy
related to adult height or type 2 diabetes, which have been
reported to be associated with higher risk for CRC as well, cannot
be fully excluded.58 In addition, Day et al. reported genetic
correlations for the 54 age at menopause SNPs with adult obesity
and other growth-related traits. The top menopause-SNPs were
also associated with fasting glucose and were enriched in DNA
repair pathways, yielding further sources of residual pleiotropy.25
Residual pleiotropy is a general limitation of MR, especially when
exploring complex traits. When considering the recently published
hypothesis of an omnigenic model of complex traits, coined
“network pleiotropy”, essentially any regulatory variant in a trait-
relevant cell-type can have some effect on the trait.59 This is
because specific cell-types have specific regulatory networks,
where any single variant could affect trait relevant genes, “core
genes”, mediated through the same regulatory networks. So also
for GWAS findings, it is highly likely that some genetic variants
exhibit horizontal pleiotropy.60 As the selected age at menarche/
age at menopause SNPs might also contribute tiny effects on
further traits through network-pleiotropy, we cannot fully rule out
pleiotropy. These limitations should be kept in mind and methods
to explore the impact of such effects should be developed. That
said, our sensitivity analyses especially Egger regression, did not
indicate large pleiotropic effects.
The second assumption of MR is that the IV is not associated
with confounding factors of the observational association
between age at menarche/menopause and CRC risk. We were
able to exclude most risk factors for CRC (smoking, family history
of CRC, education, aspirin use, MHT) as confounding variables
except for BMI, which was accounted for using several sensitivity
analyses. In addition, substantial overlap between datasets used
for estimating SNP-exposure and SNP-outcome associations
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would bias results in the direction of the observational estimate.
There was some overlap between the studies (see Supplementary
Information on participant overlap) but unlikely to have substan-
tially influenced the results.
Strengths of our study include the large sample size, the
availability of centrally harmonised data, and the robustness of the
instrumental variables. Power calculations showed that our study
has limited power to detect weak effects. Therefore, we cannot
exclude a weak association of CRC with age at menarche or age at
menopause. In summary, in our large MR study, evidence is
limited for causal associations between age at menarche/age at
menopause and CRC risk.
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Cancer Research Center, Seattle, WA 98109, USA; 22Medical Department 1, University Hospital Dresden, TU Dresden, 01307 Dresden, Germany;
23Institute of Environmental Medicine, Karolinska Institutet Solna, SE-171 77 Stockholm, Sweden; 24Epidemiology Program, University of Hawaii
Cancer Center, Honolulu 96822 HI, USA; 25Department of Clinical Genetics, Karolinska University Hospital Solna, SE-171 77 Stockholm, Sweden;
26Department of Molecular Medicine and Surgery, Karolinska Institutet Solna, SE-171 77 Stockholm, Sweden; 27Catalan Institute of Oncology,
Bellvitge Biomedical Research Institute (IDIBELL), 08028 Barcelona, Spain; 28CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
and University of Barcelona, Barcelona 08007, Spain; 29Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada; 30Department of
Family Medicine and Community Health, Case Western Reserve University, Cleveland, OH 44106, USA; 31Department of Medicine, Clinical Genetics
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Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; 32Centre for Cancer Genetic Epidemiology, Department of Public
Health & Primary Care, University of Cambridge, Cambridge CB2 8AR, UK; 33Department of Public Health Sciences, University of California, Davis,
CA 95817, USA; 34Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 35Clalit Health Services National Israeli
Cancer Control Center, Haifa 34361, Israel; 36Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa 34361, Israel;
37Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Campus Kiel, 24118 Kiel, Germany; 38Department of
Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; 39Department of Internal Medicine, University of
Utah Health Sciences Center, Salt Lake City, UT 84108, USA; 40Huntsman Cancer Institute and Department of Population Health Sciences,
University of Utah, Salt Lake City, UT 84112, USA; 41Genetic Medicine and Familial Cancer Centre, Royal Melbourne Hospital, Parkville, VIC 3050,
Australia; 42Department of Surgical Sciences, Uppsala University, Uppsala SE-171 77, Sweden; 43Faculty of Medicine, Memorial University of
Newfoundland, St. John’s, NL A1C 5S7, Canada; 44Department of Preventive Medicine, University of Southern California Keck School of Medicine,
Los Angeles, CA 90033, USA; 45Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA;
46Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg,
Germany; 47German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany and 48Genetic Tumour
Epidemiology Group, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg, 20246 Hamburg, Germany
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